MorphoSys (MOR) Competitors $18.96 0.00 (0.00%) As of 08/5/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MOR vs. VTRS, ASND, BBIO, VRNA, BPMC, LEGN, ROIV, RGC, ELAN, and RVMDShould you be buying MorphoSys stock or one of its competitors? The main competitors of MorphoSys include Viatris (VTRS), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Roivant Sciences (ROIV), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. MorphoSys vs. Its Competitors Viatris Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Legend Biotech Roivant Sciences Regencell Bioscience Elanco Animal Health Revolution Medicines MorphoSys (NASDAQ:MOR) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Is MOR or VTRS more profitable? Viatris has a net margin of -26.45% compared to MorphoSys' net margin of -226.79%. Viatris' return on equity of 16.20% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Viatris -26.45%16.20%7.01% Which has more volatility and risk, MOR or VTRS? MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Do analysts rate MOR or VTRS? Viatris has a consensus price target of $10.40, indicating a potential upside of 10.76%. Given Viatris' stronger consensus rating and higher possible upside, analysts plainly believe Viatris is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Do insiders & institutionals believe in MOR or VTRS? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 0.1% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, MOR or VTRS? MorphoSys has higher earnings, but lower revenue than Viatris. MorphoSys is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Viatris$14.74B0.75-$634.20M-$3.17-2.96 Does the media prefer MOR or VTRS? In the previous week, Viatris had 13 more articles in the media than MorphoSys. MarketBeat recorded 13 mentions for Viatris and 0 mentions for MorphoSys. Viatris' average media sentiment score of 0.29 beat MorphoSys' score of 0.00 indicating that Viatris is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Viatris Neutral SummaryViatris beats MorphoSys on 13 of the 16 factors compared between the two stocks. Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOR vs. The Competition Export to ExcelMetricMorphoSysPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.86B$785.29M$5.48B$9.57BDividend YieldN/A4.84%4.00%4.18%P/E Ratio-5.451.2929.8825.14Price / Sales11.9925.43440.19102.95Price / CashN/A19.5635.9458.58Price / Book54.176.578.105.59Net Income-$205.35M-$3.92M$3.26B$265.48M7 Day PerformanceN/A-3.14%0.65%1.22%1 Month PerformanceN/A-0.53%2.44%0.39%1 Year PerformanceN/A22.36%27.59%23.47% MorphoSys Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730VTRSViatris2.6692 of 5 stars$9.26-1.6%$10.40+12.3%-17.3%$11.04B$14.33B-2.9232,000Trending NewsEarnings ReportDividend AnnouncementShort Interest ↑Gap UpASNDAscendis Pharma A/S2.6253 of 5 stars$164.16-2.0%$223.07+35.9%+54.0%$10.24B$393.54M-26.141,017Earnings ReportBBIOBridgeBio Pharma4.7111 of 5 stars$46.23-0.2%$61.50+33.0%+92.1%$8.79B$127.42M-13.10400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeVRNAVerona Pharma PLC American Depositary Share1.8744 of 5 stars$105.09-0.2%$109.00+3.7%+439.7%$8.54B$118.54M-52.5530Trending NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.693 of 5 stars$129.46flat$129.80+0.3%N/A$8.36B$562.12M-52.41640LEGNLegend Biotech3.8424 of 5 stars$41.51-4.3%$73.33+76.7%-32.0%$7.97B$627.24M-70.352,609News CoveragePositive NewsUpcoming EarningsAnalyst RevisionROIVRoivant Sciences2.361 of 5 stars$11.35-1.7%$16.50+45.4%+13.6%$7.85B$29.05M-45.40860RGCRegencell Bioscience0.2175 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.34 of 5 stars$14.59-2.2%$16.17+10.8%+32.4%$7.41B$4.43B19.729,000Trending NewsEarnings ReportGap UpRVMDRevolution Medicines4.45 of 5 stars$37.26-1.7%$68.91+84.9%-17.3%$7.06B$11.58M-9.32250News CoverageEarnings ReportAnalyst ForecastGap Down Related Companies and Tools Related Companies VTRS Competitors ASND Competitors BBIO Competitors VRNA Competitors BPMC Competitors LEGN Competitors ROIV Competitors RGC Competitors ELAN Competitors RVMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOR) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
